Xeris Pharma

Xeris Biopharma is a commercial-stage specialty pharmaceutical company that leverages its proprietary formulation technology platforms, XeriSol and XeriJect, to develop and commercialize innovative therapies. These platforms enable the creation of ready-to-use, room-temperature stable, and low-volume liquid formulations of drugs that typically require reconstitution or are difficult to deliver. The company's commercial portfolio includes Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for Cushing's syndrome. Beyond its marketed products, Xeris maintains a robust pipeline and strategic collaborations with major biopharmaceutical companies to apply its delivery technologies to various biologics and small molecules.